LA Private

July 2024

Iron ore slumps again

It was a rough day for iron ore companies on Wednesday. After the unsettling sale of $1.9 billion worth of Fortescue (ASX:FMG) shares, global prices dipped below the US$100 a tonne mark for the second time in a week. On the SGX trading platform, prices ended Tuesday at US$99.30 a tonne for 62% Fe fines, […]

Iron ore slumps again Read More »

US job market still hot

Once again US job vacancies have confounded forecasts from economists and analysts who were looking for a slide in the number of openings. Yes they did dip – by 46,000 to 8.184 million, still well above the 6.811 million people listed as unemployed in June. But the US Bureau of Labor Statistics said the June

US job market still hot Read More »

Gold demand soars

Wealthy families and individuals concerned about US government debt levels likely drove a record surge in gold demand during the second quarter, according to an industry report, pushing the price to all-time highs this year. Private purchases of gold surged to 329 tonnes from April to June, nearly five times higher than the previous quarter,

Gold demand soars Read More »

IGO overhauls for lithium focus

IGO (ASX:IGO), the Perth-based lithium and waning nickel miner, is intensifying its strategy revamp ahead of its reveal in late August. The company indicated in its June 30 quarter and annual production and sales report on Tuesday that more job cuts are coming, on top of those already made this year, especially in the weak

IGO overhauls for lithium focus Read More »

Microsoft’s strong results ignored

The stock market reaction (after hours, it must be said) to Microsoft’s quarterly results, with higher revenue and earnings, should make you wonder if you’ve wandered into the stock market version of Alice Through the Looking Glass. The company’s shares fell almost 6% after hours (after easing 0.9% in regular trading ahead of the results

Microsoft’s strong results ignored Read More »

Clinical trials in cancer and autoimmune diseases: Immutep’s CEO Marc Voigt provides an update

Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses Phase III design for a trial in non-small cell lung cancer, positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases. Manny Anton: Hello. I’m Manny Anton for the Finance News Network, and today we’re talking to Immutep.

Clinical trials in cancer and autoimmune diseases: Immutep’s CEO Marc Voigt provides an update Read More »